Sign in Subscribe
Coronaviruses

Novel Recombinant Expression Vector for Anti-SARS-CoV-2 Neutralizing Antibodies Developed

Strategic Insights

— 1 min read

Scientists at Newsoara Biopharma Co. Ltd. have designed a recombinant expression vector that can produce highly potent neutralizing antibodies against SARS-CoV-2. The virus, responsible for the COVID-19 pandemic, has caused over 2,000,000 deaths worldwide. The recombinant expression vector is designed to deliver and produce neutralizing antibodies that can be used to treat or prevent SARS-CoV-2 infection. The vector contains an expression cassette that encodes a nucleic acid sequence for an anti-SARS-CoV-2 neutralizing antibody or antigen-binding fragments thereof.

Key Takeaways:

  • The recombinant expression vector is designed to produce an anti-SARS-CoV-2 neutralizing antibody or antigen-binding fragments thereof.
  • The vector contains an expression cassette that encodes a nucleic acid sequence for the antibody, which includes heavy chain CDR (HCDR)1, HCDR2, and HCDR3, and light chain CDR (LCDR)1, LCDR2, and LCDR3.
  • The vector can be used to treat or prevent SARS-CoV-2 infection in individuals identified as having the infection, suspected of having the infection, or at risk of exposure to the virus.
  • The recombinant expression vector can be administered as a pharmaceutical composition in combination with a pharmaceutically acceptable carrier.
  • The vector can be used as a method of treating or preventing SARS-CoV-2 infection in a subject, making it a promising tool in the fight against COVID-19.

Statistics:

  • Over 2,000,000 deaths have been reported worldwide due to SARS-CoV-2 infection.
  • The recombinant expression vector is designed to produce highly potent neutralizing antibodies against SARS-CoV-2.
  • The vector can be used to treat or prevent SARS-CoV-2 infection in individuals identified as having the infection, suspected of having the infection, or at risk of exposure to the virus.

Sources:

  • Li, Yuannian. Expression vector for anti-SARS-CoV-2 neutralizing antibodies. U.S. Patent Number 11312760, filed August 2, 2021, and published online on April 26, 2022.
  • Patent URL: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=11312760.PN.&OS=PN/11312760RS=PN/11312760

Read more